Live tape
Top 8, mentions 7d7,505META2,263 mentions▲ +0.06GOOGL1,504 mentions▲ +0.02NVDA797 mentions▲ +0.09MUSE665 mentions▲ +0.07MSFT602 mentions▲ +0.05SPY567 mentions▲ +0.05QQQ557 mentions▲ +0.08TSLA550 mentions▲ +0.06

Equity · Healthcare

EWTX

Edgewise Therapeutics, Inc. · NasdaqGS

$40 +4.77% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
Our own end-of-day closes 13 sessions
$50 $35 30 Jun 17 Jul

The line runs $41 on 30 June through $40 on 17 July, on a scale from $35 to $50. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of EWTX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 13 sessions over that window: $41 on 30 June 2026 through $40 on 17 July 2026.

Market cap $4.3B
52-week range $12.66 – $48
Avg volume 344.7K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026

EWTX insider trades

SEC Form 4

EWTX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 19 November 2025.

Date Insider Type Shares Value
12 Nov 2025 Russell Alan J Chief Scientific Officer Sell 100,000 $2.11M
11 Nov 2025 Fox Jonathan C Buy 10,700 $199K
26 Aug 2025 Russell Alan J Chief Scientific Officer Sell 100,000 $1.46M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
19 Nov 2025 Martin Christopher Nathan Award 45,150
12 Nov 2025 Russell Alan J Chief Scientific Officer Option exercise 100,000 $18K
10 Nov 2025 Nofi Michael Chief Financial Officer Award 306,250
01 Oct 2025 Fox Jonathan C Award 728
26 Aug 2025 Russell Alan J Chief Scientific Officer Option exercise 100,000 $18K

EWTX reported financials

SEC EDGAR XBRL

EWTX reported net income of −$167.8M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$167.8M 31 Dec 2025 fiscal year
Diluted EPS −$1.63 31 Dec 2025 fiscal year
Total assets $479.7M 30 Jun 2026 at period end
Total equity $448.1M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

EWTX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.53 —
31 Mar 2026 Q1 2026 $-0.46 —
31 Dec 2025 FY 2025 $-1.63 —
30 Sep 2025 Q3 2025 $-0.39 —
30 Jun 2025 Q2 2025 $-0.34 —
31 Mar 2025 Q1 2025 $-0.43 —
31 Dec 2024 FY 2024 $-1.45 —
30 Sep 2024 Q3 2024 $-0.36 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

EWTX institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a EWTX position for the quarter ended 30 Jun 2026 — a combined $187.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Trimmed −43.7% shares 3,701,719 $150.4M
Citadel Advisors Held (±25%) +9.5% shares 469,707 $19.1M
D. E. Shaw & Co. Added +80.3% shares 189,115 $7.7M
Point72 Asset Management New position 117,262 $4.8M
Tudor Investment Corp Added +90.5% shares 56,934 $2.3M
Two Sigma Investments Held (±25%) −2.6% shares 49,548 $2.0M
AQR Capital Management Added +116.1% shares 18,456 $750K
Marshall Wace Trimmed −99.1% shares 6,100 $248K
Millennium Management Exited

Source: SEC EDGAR 13F filings

EWTX fails-to-deliver

SEC CNS data

On 31 Aug 2026, 17,000 shares of EWTX failed to deliver (about $727K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 17,000 $727K 0.016%

Source: SEC fails-to-deliver (CNS) data